The James Buchanan Brady Urological Institute
 
 
 
Michael A. Carducci, MD Michael A. Carducci, M.D., FACP
Professor in Oncology and Urology
Johns Hopkins Medical Institutions

Email:carducci@jhmi.edu

PUBLICATIONS

Peer-Reviewed Original Research Articles

  1. Twillie DA, Eisenberger MA, Carducci MA, Hseih WS, Kim WY, and Simons JW.  Interleukin 6:  A candidate gene product in the molecular biology of human prostate cancer morbidity.  Urology. 1995: 45: 542-549.
  2. Carducci MA, Ayyagari SA, Sanda MG, Simons JW.  Gene therapy for prostate cancer: translational research from the Dunning prostate cancer model.  Cancer.1995; 75: 2013-2020.
  3. Carducci MA, Nelson JB, Chan-Tack K, Ayyagari SR, Sweatt WH, Campbell PS, Nelson WG,  Simons JW.  Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate.  Clin Can Res.1996; 2:379-385.
  4. Carducci MA, Abrams R, Yeo C, Hruban RV, Zahurak M, Cameron J, Grochow L.  Early evaluation of abdominal/hepatic irradiation and 5-FU/Leucovorin after pancreaticoduodenectomy.  Intl Jour of Radiation Onc, Biology, Physics.  1996;35:143-150.
  5. Simons JW, Jaffee EM, Weber C, Levitsky HI, Nelson WG, Carducci MA, Lazenby AJ, Cohen L, Finn CC, Clift SM, Hauda KM, Owens AH, Pardoll DM, Piantadosi S,  Dranoff G, Mulligan RC,  Marshall FF.  Bioactivity of human GM-CSF gene transfer in autologous irradiated renal cell carcinoma vaccines.  Cancer Research. 1997; 57:1537- 1546.
  6. Healy CG, Simons JW, Carducci MA, DeWeese TL , Bartkowski M, Tong KP, Bolton WE.  Impaired    expression  and function of signal transducing z-Chains in peripheral T cells and natural killer cells in patients with prostate cancer. Cytometry. 1998; 32: 109-119.
  7. Carducci MA, Choti MA, Maestri NE, Brusilow SW.  Allopurinol-induced pyrimidinuria in cancer patients.  In Vivo. 1998; 12: 271-274.
  8. Pelidis MA, Carducci MA, Simons JW.  Cytotoxic effects of sodium phenylbutyrate on human neuroblastoma cell lines. International Journal of Oncology. 1998; 12: 889-893.
  9. Carducci MA, Piantadosi S,  Pound CR, Epstein JI, Simons JW, Marshall FF,  Partin A.  Nuclear morphometry adds significant prognostic information to stage and grade of renal cell carcinoma.  Urology. 1999; 53: 44-49.
  10. Simons JW, Mikhak B, Chang J-F, DeMarzo AM, Carducci MA, Lim M, Weber CE, Baccala AA, Goemann MA, Clift SM, Ando DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC, Partin AW, Carter B, Piantadosi S, Marshall FF, Nelson WG.  Induction of immunity to prostate cancer antigens:  Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete GM-CSF using ex-vivo gene transfer. Cancer Res.  1999; 59: 5160-5168.
  11. Bubley GJ, Carducci MA, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP,Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Vollmer R, Wilding G.  Eligibility and response guidelines for phase II clinical trials in androgen independent prostate cancer: recommendations from the PSA working group. J Clin Oncol.  1999; 17: 1-7.
  12. Sinibaldi VJW, Carducci M, Laufer M, Eisenberger M.  Preliminary evaluation of a short course of estramustine phosphate and docetaxel (Taxotere) in the treatment of hormone-refractory prostate cancer.  Semin Oncol.  1999; 26 (Suppl 17) 45-48.
  13. Laufer M, Sinibaldi VJ, Carducci MA, Eisenberger MA.  Rapid disease progression after the administration of bicalutamide in patients with metastatic prostate cancer. Urology. 1999; 54: 745.
  14. Wang, Z-.P, Eisenberger MA, Carducci MA, Partin AW, Scher HI,  T’so POP.  Identification and characterization of circulating prostate cancer cells.  Cancer. 2000; 88: 2787-2795.
  15. Kaufman D, Raghavan D, Carducci M, Levine EG, Murphy B, Aisner J, Kuzel T, Nicols S, Oh W, and Stadler W.  A phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer.  J Clin Oncol.  2000; 18:1921-1927.
  16. Nelson WG, Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Kim M, Weber CE, Baccala AA, Goeman MA, Clift SM, Ando DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC, Partin AW, Carter HB, Piantadosi S, Marshall FF.  Cancer cells engineered to secrete granulocyte-macrophage colony stimulating factor using ex-vivo gene transfer as vaccines for the treatment of genitourinary malignancies.  Cancer Chemother Pharmacol. 2000; 46: S67-72.
  17. Pili R, Kruszewski MP, Hager B, Lantz J, Carducci MA.  Combination of phenylbutyrate and 13-cis-retinoic acid inhibits prostate tumor growth and angiogenesis. Cancer Res. 2001; 61: 1477 – 1485.
  18. Carducci MA, Gilbert J, Bowling MK, Eisenberger MA, Sinibaldi V, Noe D, Chen TL, Grochow LB, Donehower RC.  A phase I clinical and pharmacologic evaluation of sodium phenylbutyrate on a 120 hours infusion schedule.  Clin Cancer Res. 2001; 7: 3047-3055.
  19. Gilbert J, Baker SD, Bowling MK, Grochow L, Figg WD, Zabelina Y, Donehower RC, Carducci MA.   A phase I dose escalation trial to maximally tolerated dose of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res. 2001; 7: 2292 - 2300.
  20. Roberts WW, Bergstralh EJ, Blute ML, Slezak JM, Carducci MA, Han M, Epstein JI, Eisenberger MA, Walsh PC, Partin AW.  Contemporary identification of patients at high risk  for early prostate cancer recurrence following radical retropubic prostatectomy. Urology. 2001; 57: 1033-1037.
  21. DeWeese TL, Mikhak B, Drew R, Goemann M, Li S, Hamper U, DeJong R, Detorie N, van der Poel H, Rodriquez R, Haulk T, DeMarzo AM, Piantadosi, S, Carducci MA, Nelson WG, Simons JW.  A phase I trial of intraprostatic CN706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of prostate cancer which is locally-recurrent following radiation therapy.  Cancer Res. 2001; 61: 7464-7472.
  22. Van der Poel HG, McCadden J, Verhaegh GW, Kruszewski M, Ferrer F, Schalken JA, Carducci M, Rodriguez R.  A novel method for the determination of basal gene expression of tissue specific promoters:  An analysis of prostate specific promoters.   Cancer Gene Ther. 2001; 8: 927-935.
  23. Heath EI, O’Reilly S, Humphrey R, Sundaresan P, Donehower RC, Sartorius S, Kennedy MJ, Armstrong DK, Carducci MA, Sorensen JM, Kumor K, Kennedy S, Grochow LB.  Phase I trial of the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced solid tumors.  Cancer Chemother Pharmacol. 2001; 48:269-274.
  24. Carducci MA, Bowling MK, Rogers T,  Eisenberger M, Sinibaldi V, Donehower R, Leahy T,  Moyse D, Carr R, Isaacson J, Janus TJ, Padley RJ, Nelson JB.  Atrasentan, an endothelin receptor antagonist for refractory adenocarcinomas: Phase I and pharmacologic evaluation.  J Clin Oncol. 2002; 20: 2171-2180.
  25. Sinibaldi VJ, Carducci MA, Moore-Cooper S, Laufer M, Zahurak M, Eisenberger MA.   Phase II evaluation of docetaxel plus one day oral estramustine phosphate in the treatment of androgen independent prostate cancer.  Cancer. 2002; 94: 1457-1465.
  26. Li Y, McCadden J. Ferrer F, Kruszewski M, Carducci M, Simons J, Rodriguez R.  Prostate-specific expression of the diptheria tox A chain: Studies of inducibility and specificity of expression of prostate-specifc antigen promoter-driven DT-A adenoviral mediated gene transfer.  Cancer Res. 2002; 62: 2576-2582.
  27. Basaria S, Lieb J, Tang AM, DeWeese T, Carducci M, Eisenberger M, Dobs AS.  Long – term effects of androgen deprivation therapy in prostate cancer patients.  Clin Endocrinol. 2002; 56: 779-786.
  28. Heath EI, DeWeese TL, Partin AW, DeMarzo AM, Groopman JD, Nelson WG, Rodriguez R, Piantadosi SA, Carter HB, Schoenberg MP, Yang VW, Hubbard WC, Dannenberg AJ, Lieberman R, Walczak J, Gurganus R, Stewart J, Carducci MA.  The design of a randomized, placebo-controlled trial of celecoxib in pre-prostatatectomy men with clinically localized adenocarcinoma of the prostate.  Clin Prostate Cancer. 2002; 1: 182-187.
  29. Carducci MA, Padley RJ, Breul J, Vogelzang NJ, Zonnenberg BA, Daliani DD, Schulman CC, Nabulsi AA, Humerickhouse RA, Weinberg MA,  Schmitt JL, Nelson JB.  The effect of endothelin-A receptor blockade with atrasentan on tumor prgression in men with hormone refractory prostate cancer: A randomized, placebo controlled trial. J Clin Oncol. 2003; 21: 679-689.
  30. Nelson JB, Nabulsi AA, Vogelzang NNJ, Breul J, Zonnenberg BA, Daliani DD, Schulman CC, Carducci MA.  Suppression of prostate cancer-induced bone remodeling by the endothelin receptor A antagonist, atrasentan.  J Urology. 2003; 169: 1143-1149.
  31. Wolff AC, Donehower RC, Carducci MK, Carducci MA, Brahmer JR, Zabelina Y, Bradley MO, Anthony FH, Swindell CS, Witman PA, Webb NL, Baker SD.  Phase I study of DHA-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile.  Clin Cancer Res. 2003; 9: 3589-3597.
  32. Eisenberger MA, Laufer M, Vogelzang N, Sartor O, Thornton D, Neubauer BL, Sinibaldi V, Lieskovsky G, Carducci MA, Zahurak M, Raghavan D.  Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY-320236) in prostate cancer: Insights on the possible mechanism of action.  Urology. 2004; 63: 114-119.
  33. Scher HI, Eisenberger M, D’Amico AV, Halabi S, Small EJ, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci MA, Agus D, Slovin SF, Heller G, Kelly WK, Lange PH, Petrylak D, Berg W, Higano C, Wilding G, Moul JW, Partin AW, Logothetis C, Soule H.  Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the prostate-specific antigen working group.  J Clin Oncol. 2004; 22: 537-556.
  34. Sunkara U, Walczak J, Summerson L, Rogers T, Eisenberger M, Denmeade S, Pili R, Huff C, Sinibaldi V, Carducci M. A phase II trial of temozolamide and interferon-alpha in patients with advanced renal cell carcinoma.  J of Interferon and Cytokine Res. 2004; 24: 37-41.
  35. Baker SD, Zhao M, He P, Carducci MA, Verweij J, Sparreboom A.  Simultaneous analysis of docetaxel and the formulation vehicle polysorbate 80 in human plasma by LC/MS/MS.  Anal Biochem. 2004; 324: 276-284.
  36. Baker SD, Zhao M, Lee CKK, Verweij J, Zabelina Y, Brahmer JR, Wolff AC, Sparreboom A, Carducci MA.  Comparative pharmacokinetics of weekly and every 3-week docetaxel.  Clin Cancer Res. 2004; 10: 1976-1983.
  37. Kaufman DS, Carducci MA, Kuzel T, Todd MB, Oh WK, Smith MR, Nicol SJ, Stadler WM.  A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer.  Urol Oncol. 2004; 22: 393-397.
  38. Lin KS, Luu A, Baidoo KE, Hashemzadeh-Gargari H, Chen MK, Pili R, Pomper M, Carducci M, Wagner HN Jr. A new high affinity technetium analogue of bombesin containing DTPA as a pharmacokinetic Modifier.  Bioconjug Chem. 2004; 15: 1416-1423.
  39. Zhao M, Rudek MA, He P, Hartke C, Gore S, Carducci MA, Baker SD.  Quantification of 5-azacytidine in plasma by electrospray tandem mass spectrometry with high-performance liquid chromatography.  J Chromatog B. 2004; 813: 81-88.
  40. Baker SD, van Schaik RHN, Rivory LP, Dinh K, Graveland WJ, Schenk PW, Charles KA, Clarke SJ, Carducci MA, McGuire WP, Dawkins F, Gelderblom H, ten Tije AJ, Verweij J, Sparreboom A.  Factors affecting cytochromome P-450 3A activity in cancer patients.  Clin Cancer Res. 2004; 10: 8341-8350.
  41. Lin K-S, Luu A, Baidoo KE, Hashemzadeh-Gargari H, Chen M-K, Brenneman K, Pili R, Pomper M, Carducci MA, Wagner HN.  A new high affinty technetium-99m-bombesin analogue with low abdominal accumulation.  Bioconjugate Chem. 2005; 16: 43-50.
  42. Dees EC, Baker SD, O’Reilly S, Rudek MA, Davidson SB, Aylesworth C, Elza-Brown K, Carducci MA, Donehower RC.  A phase I and pharmacokinetic study of short infusions of the protein kinase C inhibitor UCN-01 in patients with refractory solid tumors.  Clin Cancer Res. 2005; 11: 664-671.
  43. ten Tije AJ, Verweij J, Carducci MA, Rogers T, Pronk T, Verbruggen MP, Dawkins F, Baker SD.  Prospective evaluation of the pharmacokinetics, CYP3A phenotype, and toxicity profile of docetaxel in the elderly.  J Clin Oncol. 2005; 23: 1070-1077.
  44. Phupanich S, Baker SD, Grossman SA, Carson KA, Gilbert MR, Fisher JD, Carducci MA.  Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: A Phase I clinical and pharmacological study.  Neuro Oncol. 2005; 7: 177-182.
  45. Rudek MA, Zhao M, He P, Hartke C, Gilbert J, Gore SD, Carducci MA, Baker SD.  Pharmacokinetics of 5-azacytidine given with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. J Clin Oncol. 2005; 23: 3906-3911. 
  46. Carducci MA, Carrol PR.  Multidisciplinary managemenet of advanced prostate cancer: Changing perspectives on referring patients and enhancing collaboration between oncologists and urologists in clinical trials.  Urol. 2005; 65(S5A) 18-22.
  47. Rosenbaum E, Zahurak  M, Sinibaldi V, Carducci MA, Pili R, Laufer M, DeWeese TL, Eisenberger MA.  Marimistat in the treatment of patients with biochemically relapsed prostate cancer: A prospective randomized double blind Phase I/II trial.  Clin Cancer Res., 2005; 11: 4437-4443.
  48. Huie M, Carducci M, Liu G, Wilding G, Marnocha R, Izquierda M, Thomas J.  Phase I trial of piritrexim and gemcitabine in patients with advanced solid tumors.  Am J Clin Oncol.  2005; 28: 613-617.
  49. Basaria S, Muller D, Carducci M, Egan J, Dobs AS.  Hyperglycemia and insulin resistance in men with prostate cancer undergoing androgen deprivation therapy.  Cancer.  2006; 106: 581-588.
  50. Messersmith WA, Baker SD, Lassiter L, Sullivan RA, Dinh K, Almuete VI, Wright JJ, Donehower RC, Carducci MA, Armstrong DK. Phase I trial of bortezomib (PS-341) in combination with docetaxel in patients with advanced solid tumors.  Clin Cancer Res. 2006; 12: 1270-1275.
  51. Gray R, Manola J, Saxman S, Wright J, Dutcher J, Atkins M, Carducci M, Morton R, See W, Sweeney C, Liu G, Dreicer R, DiPaola R.  The future of phase II clinical trial design: Methods in translational research from the genitourinary committee of the Eastern Cooperative Oncology Group.  Clin Cancer Res.  2006; 12: 1966-1969.
  52. Braga-Basaria M, Muller DC, Carducci MA, Egan J, Dobs AS, Basaria S.  Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy. Intl J Impot Res. 2006; 18: 494-498.
  53. Gilbert J, Carducci MA, Dees EC, Baker SD, Donehower RD.  A Phase I study of the oral anti-metabolite, CS-682, administered once daily 5 days per week in patients with refractory solid tumor malignancies.  Invest New Drugs.  2006; 24: 499-508.
  54. Small EJ, Carducci MA, Burke JM, Rodriguez R, Fong L, van Ummerson L,Yu DC, Aimi J, Ando D, Working P, Kirn D, Wilding G.  A Phase I trial of intravenous CG7870, a replication-selective PSA-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.  MolTher. 2006; 14: 107-117.
  55. Green LJ, Marder P, Ray C, Cook CA, Jaken S, Herbst R, Carducci M, Britten C, Basche M, Eckhardt G, Thornton D.  Development and validation of a drug activity biomarker that demonstrates target inhibition in cancer patients receiving enzastaurin, a novel phospho-kinase C-b inhibitor. Clin Cancer Res. 2006; 12: 3408-3415.
  56. Simons JW, Carducci MA, Mikhak B, Lim M, Biedrzycki B, Borellini F, Clift Sm, Hege KM, Ando DG, Piantadosi S, Mulligan R, Nelson WG.  Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer.  Clin Cancer Res. 2006; 12: 3394-3401.
  57. Gore SD, Baylin S, Sugar E, Carraway H, Miller CB, Carducci M, Grever M, Galm O, Dauses T, Karp JE, Rudek MA, Zhao M, Smith BD,  Manning J, Jiemjit A, Dover G, Mays A, Zweibel J, Murgo A, Weng L-J, Herman J.  Combined DNA methyltransferase and histone deacetylation inhibition in the treatment of myeloid neoplasms.  Cancer Res. 2006; 66: 6361-6369.
  58. Maggio M, Blackford A, Taub D, Carducci M, Ble A, Metter J, Braga-Basaria M, Dobs A, Basaria S.  Circulating inflammatory cytokine expression in men with prostate cancer undergoing androgen deprivation therapy. J Androl  2006;27; 725-728.
  59. Xia Q, Sung J, Chowdhury W, Chen C-L, Hoti N, Shabbeer S, Carducci M, Rodriquez R.  Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro.  Cancer Res. 2006; 66: 7237-7244.
  60. Sinibaldi VJ, Elza-Brown K, Schmidt J, Eisenberger MA, Rosenbaum E, Denmeade SR, Pili R,  Walczak J, Baker SD, Zahurak M, Carducci MA.  Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma.  Am J Clinical Oncol. 2006; 29: 395-398.
  61. Braga-Basaria M, Muller DC, Carducci MA, Egan J, John M, Dobs AS, Basaria S.  Metabolic syndrome in men with prostate cancer undergoing long-term androgen deprivation therapy.  J Clin Oncol.  2006; 24: 3979-3983.
  62. Carducci MA, Musib L, Kies M, Pili R, Truong M, Brahmer JR, Cole P, Sullivan R, Riddle J, Stewart J, Enas N, Sinha V, Thornton DE, Herbst RS. Dose escalation and pharmacokinetics of enzastaurin (LY317615), an oral PKCb inhibitor, in patients with advanced cancer: a Phase I study.  J Clin Oncol. 2006; 24: 4092-4099.
  63. Qian DZ, Kachhap SK, Collis SJ, Verheul HMW, Carducci MA, Atadja P, Pili R. Class II histone deacetylases are associated with VHL independent regulation on HIF-1a.  Cancer Res. 2006; 66: 8814-8821.
  64. Levy MH, Back A, Bazargan S, Benedetti C, Billings JA, Block S, Bruera E, Carducci MA, Dy S, Eberle C, Foley KM, Harris JD, Knight SJ, Milch R, Rhiner M, Slatkin NE, Spiegel D, Sutton L, Urba S, Von Roenn JH, Weinstein SM.  Palliative Care.  J Natl Compr Canc Netw. 2006; 4: 776-818.
  65. Messersmith WA, Rudek MA, Baker SD, Zhao M, Collins C, Colevas AD, Donehower RC, Carducci MA, Wolff AC.  Phase I study of continuous weekly dosing of dimethyl benzolphenylureas (BPU) in patients with solid tumors.  Europ J Cancer. 2007; 43: 78-86. Epub 2006 Nov 3.
  66. Motzer RJ,  Bolger GB, Boston B, Carducci MA, Fishman M, Hancock SL, Hauke RJ, Hudes GR, Jonasch E, Kantoff P, Kuzel TM, Lange PH, Levine EG, Logothetis C, Margolin KA, Pohar K, Redman BG, Robertson CN, Samlowski WE, Sheinfeld J. Kidney cancer.  J Natl Compr Canc Netw. 2006; 4: 1072-1081.
  67. Motzer RJ,  Bolger GB, Boston B, Carducci MA, Fishman M, Hancock SL, Hauke RJ, Hudes GR, Jonasch E, Kantoff P, Kuzel TM, Lange PH, Levine EG, Logothetis C, Margolin KA, Pohar K, Redman BG, Robertson CN, Samlowski WE, Sheinfeld J. Testicular Cancer.  J Natl Compr Canc Netw. 2006;4: 1038-1058.
  68. Verheul HMW, Qian DZ, Carducci MA, Pili R.   Sequence-dependent antitumor effects of differentiation agents in combination with cell cycle-dependent cytotoxic drugs.  Cancer Chemother Pharmacol, 2007; 60:329-339. [Epub 2007 Jan 26].
  69. Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta G, Ruether D, Redfern CH, Fehrenbacher L, Saleh MN, Waterhouse D, Carducci MA, Vicario D, Dreicer R, Higano CS, Ahmann FR, Chi KN, Henner WD, Arroyo A, Clow FW.  ASCENT: A double-blinded randomized study of DN-101 (high dose calcitriol)plus docetaxel versus placebo  plus docetaxel in androgen –independent prostate cancer.  J Clin Oncol, 2007; 25: 669-674.
  70. Snyder CF, Dy SM, Hendricks DE, Brahmer JR, Carducci MA, Wolff AC, Wu AW.  Asking the right questions: Investigating needs assessments and health-related quality of life questionaires for use in oncology clinical practice. Suppor Care Cancer, 2007, 15:1075-1085.  [Epub 2007 Feb 21].
  71. Bajaj GK, Zhang Z, Garrett-Mayer E, Drew R, Sinibaldi V, Pili R, Denmeade SR, Carducci MA, Eisenberger MA, Deweese TL. Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy.  Urology 2007; 69:626-531.
  72. Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS. Relation between duration of androgen deprivation therapy and degree of insulin resistance in men with prostate cancer.  Arch Int Med, 2007; 167:612-613.
  73. Jimeno A, Rudek MA, Purcell T, Laheru DA, Messersmith W, Dancey J, Carducci MA, Baker SD, Hidalgo M, Donehower RC.  Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors. Cancer Chem Pharmacol, 2008; 61: 423-433. [Epub 2007 Apr 12].
  74. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawskka E, Sosman J, Atkins M, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf I, Barbarash O, Gokmen E, Galand L, Thiele A, O’Toole T, Kong S, Park Y, Moore L, Motzer R.  Temsirolimus, interferon, or the combination of interferon plus temsirolimus for patients with advanced renal cell carcinoma and poor risk features. N Engl J Med, 2007; 356:2271-2281.
  75. Zhou S, Kachhap S, Sun W, Wu G, Chuang A, Poeta L, Grumbine L, Mithani S, Chatterjee A, Koch W, Westra W, Maitra A, Glazer C, Carducci M, Sidransky S, Mcfate T, Verma A, Califano JA.  Frequency and phenotypic implications of mitochondrial DNA mutations in human squamous cell cancers of the head and neck. Proc Natl Acad Sci. 2007; 104: 7540-7545. [Epub 2007 Apr 24].
  76. Shabbeer S, Kortenhorst M, Kachhap S, Galloway N, Rodriguez R, Carducci MA.  Multiple molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo.  The Prostate, 2007; 67: 1099-1110.
  77. Armstrong A, Garrett-Mayer E, Yang Y-C-0, Carducci M, Tannock I, de Wit R, Eisenberger M.  PSA and pain surrogacy analysis in metastatic hormone-refractory prostate cancer.  J Clin Oncol, 2007; 25:3965-3970.
  78. Kachhap S, Faith D, Qian D, Shabbeer S, Galloway N, Pili R, Denmeade S, DeMarzo A, Carducci M The N-myc Down Regulated Gene1 (NDRG1) is a Rab4a Effector Involved in Vesicular Recycling of E-cadherin. PLoS One 2007; Sep 5;2 (9): e844.
  79. Collins C, Carducci MA, Eisenberger MA, Isaacs JT, Partin AW, Pili R, Sinibaldi VJ, Walczak JS, Denmeade SR. Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint. Cancer Biol Ther. 2007; Jun 5; 6 (9). [Epub ahead of print].
  80. Carducci MA, Saad F, Abrahamsson P-A, Dearnaley DP, Schulman CC, North SA, Sleep DJ, Isaacson JD, Nelson JB. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer.  Cancer. 2007; 110: 1959-1966.
  81. Makarov DV, Humphreys EB, Mangold LA, Carducci MA, Partin AW, Eisenberger MA, Walsh PC, Trock BJ.  The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy.  J Urol 2008; 156-162.  Epub 2007 Nov 14.
  82. Baselga J, Rothenberg ML, Tabernero J, Seoane J, Daly T, Cleverly A, Berry B, Rhoades SK, Ray CA, Fill J, Farrington DL, Wallace LA, Yingling JM, Lahn M, Arteaga C, Carducci M.  TGF-β signaling related markers in cancer patients with bone metastasis.  Biomarkers. 2008;13:217-236.
  83. Scher HI, Halabi S, Tannock IF, Morris MJ, Sternberg CN, Carducci MA, Eisenberger MA, Higano CS, Bubley GJ, Dreicer R, Petrylak DP, Kantoff PW, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M.  Design and endpoints of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group (PCWG2).  J Clin Oncol, 2008; 26: 1148-1159.
  84. Rudin CM, Liu W, Desai A, Karrison T, Jiang X, Jahisch L, Das S, Ramirez J, Poonkuzhali B, Schuetz E, Fackenthal DL, Chen P, Armstrong DK, Brahmer JR, Fleming GF, Vokes EE, Carducci MA, Ratain MJ.  Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.  J Clin Oncol, 2008; 26: 1119-1127.
  85. Siu LL, Pili R, Duran I, Messersmith WA, Chen EX, Sullivan R, MacLean M, King S, Brown S, Reid GK, Li Z, Kalita AM, Laille EJ, Besterman JM, Martell RE, Carducci MA.  A phase I study of MGCD0103 given as a three-times per week oral dose in patients with advanced solid tumors.  J Clin Oncol, 2008; 26: 1940-1947. 
  86. Hooker A, ten Tije AJ, Carducci M, Weber J, Garret-Mayer E, Gelderblom H, McGuire W, Verweij J, Karlsson M, Baker S.  Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: Incorporating cytochrome P450 3A activity measurements.  Clin Pharmacol Ther  2008; 84:111-118. Epub 2008 Jan 9.  
  87. Alumkal J, Carducci MA, Partin AW, Walsh PC, Herman JG.  Impact of DNA methylation on the identification of aggressive prostate cancer.  Urology, 2008; 72:1234-1239. Epub 2008 Apr 2.  
  88. Lassiter LK, Tummala MK, Hussain MH, Stadler WM, Petrylak DP, Carducci MA.  Phase II open label study of oral piritrexim in patients with advanced carcinoma of the urothelium who have failed standard chemotherapy.  Clin Genitourinary Cancer, 2008; 6:31-35.   
  89. Snyder CF, Garrett-Mayer E, Brahmer JR, Carducci MA, Pili R, Stearns V, Wolff AC, Dy SM, Wu AW.  Symptoms, supportive care needs, and function in cancer patients: How are they related?  Qual Life Res, 2008; 17:665-677.  Epub 2008 May 21.   

  90. Bonfils C, Kalita A, Dubay M, Siu LL, Carducci MA, Reid G, Martell RE, Besterman JM, Li Z.  Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human, using a novel HDAC enzyme assay.  Clin Cancer Res, 2008;14: 3442-3449.

  91. Baker SD, Verweij J, Cusatis GA, van Schaik RH, Marsh S, Orwick SJ, Franke RM, Hu S, Schuetz EG, Lamba V, Messersmith WA, Wolff AC, Carducci MA, Sparreboom A.  Pharmacogenetic pathway analysis of docetaxel elimination.   Clin Pharmacol Therap, 2008; 85:155-163.  Epub 2008 May 28.  

  92. Rathkopf D, Carducci MA, Morris M, Slovin S, Eisenberger M, Pili R, Denmeade S, Kelsen M, Curley T, Halter M, Collins C,  Fleisher M, Heller G,  Baker SD, Scher HI  Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer.  J Clin Oncol 2008; 26: 2959-2965.

  93. O’Brien PJ, Ramanathan R, Yingling JM, Baselga J, Rothenberg ML, Carducci M, Daly T, Adcock D, Lahn M. Analysis and variability of TGFβ measurements in cancer patients with skeletal metastases.   Biologics; Targets and Therapy. 2008 June 13 [Epub ahead of print].

  94. Kass N, Taylor H, Fogarty L, Sugarman J, Goodman SN, Goodwin-Landher A, Carducci M, Hurwitz H. Purpose and benefits of early phase cancer trials: What do oncologists say? What do patients hear?  J Empirical Res Human Res Ethics 2008; 3:57-68.

  95. Heath E, Hillman D, Vaishampayan U, Sheng S, Sarkar F, Harper F, Gaskins M, Pitot H, Tan W, Ivy P, Pili R, Carducci MA, Erlichman C, Liu G.  A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone refractory prostate cancer.  Clin Cancer Res, 2008, 14: 7940-7946.

  96. Nelson JB, Love W,  Chin JL, Saad F, Schulman CC, Sleep DJ, Qian J, Steinberg J, Carducci M.  Phase 3, randomized controlled trial of atrasentan in patients with nonmetastatic hormone refractory prostate cancer.  Cancer, 2008; 113: 2478-2487.


  97. Kortenhorst MSQ, Zahurak M, Shabbeer S, Kachhap S, Galloway N, Parmigiani G, Verheul HMW, Carducci MA.  A multiple loop, double cube microarray design applied to prostate cancer cell lines with variable sensitivity to histone deacetylase inhibitors.  Clin Cancer Res, 2008; 14: 6886-6894.

  98. Shabbeer S, Kumar-Anchoori R, Kachhap S, Davidson N, Carducci MA, Khan SR.  Fenugreek: A naturally occurring edible material as an anticancer agent.  Cancer Biol Ther 2009 Feb 18; 8 (3). 

  99. Kortenhorst MSQ, Isharwal S, van Diest PJ, Chowdhury WH, Marlow C, Carducci MA, Rodriguez R, Veltri RW.  Valproic acid causes dose and time dependent changes in nuclear structure in prostate cancer cells in vitro and in vivo.  Mol Cancer Ther, 2009, 8:802-808.

  100. Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, Yu G, Chen L, Ewing CM, Eisenberger MA, Carducci MA, Nelson WG, Yegnasubramanian S, Luo J, Wang Y, Xu J, Isaacs WB, Visakorpi T, Bova GS.  Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer.  Nat Med,  2009, Apr 12. [Epub ahead of print]

  101. Antonarakis ES, Heath EI, Walczak JR, Nelson WG, DeMarzo AM, Zahurak ML, Piantadosi S, Dannenberg AJ, Gurganus RT, Baker SD, Parnes HL, DeWeese TL, Partin AW, Carducci MA.  A randomized, placebo controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: Evaluation of drug-specific biomarkers.  J Clin Oncol, 2009, in press.

     

Review Articles

 

  1. Eisenberger M, Reyno L, Sinibaldi V, Sridhara R, Carducci M, Egorin M.  The experience with Suramin in advanced prostate cancer.  Cancer 1995; 75: 1927-1934.

  2. Carducci MA, DeWeese TL, Nelson WG, Simons JW, Sinibaldi V, Eisenberger MA.  Prostate cancer treatment strategies based on tumor-specific biological principles: Future directions.  Seminars in Oncology,  1996; 23(6):56-62.


  3. Carducci MA.  Differentiation as a therapeutic target. Cancer Research Therapy and Control.  1998; 7: 2443-2446.

  4. Carducci MA, DeWeese TL, Nelson JB.  PSA and other markers of therapeutic response. Urologic Clinics of North America. 1999; 26:291-302.

  5. Laufer M, Carducci MA, Blumenstein B, Eisenberger MA.  Combined androgen blockade (CAB) for the treatment of patients with metastatic prostatic cancer: Summary of 15 years of Clinical Research. AUA Update Series. 1999; 18(29):226-231.

  6. Nelson JB, Carducci MA.  The role of the endothelin axis in prostate cancer.  The Prostate Journal. 1999; 1(3):126-130.

  7. Nelson JB, Carducci MA, The role of small bioactive peptides and cell surface peptidases in androgen-independent prostate cancer.  Cancer Investigation.  2000; 18: 87 – 96.

  8. Wood HM, Carducci MA.  Differentiation therapy for prostate cancer:  The Prostate Journal, 2000; 2: 6-13.

  9. Laufer M, Pound CR, Carducci MA, Eisenberger MA.  Management of patients with rising prostate-specific antigen after radical prostatectomy. Urology. 2000; 55: 309-315.

  10. Nelson JB, Carducci MA.  The role of endothelin-1 and and endothelin receptor antagonists in prostate cancer.  Br J Urol. 2000; 85(2): 45-48.

  11. Laufer M, Denmeade S, Sinibaldi V, Carducci M, Eisenberger MA.  Complete androgen blockade for prostate cancer:  What went wrong.  J Urol. 2000; 164: 3-9.

  12. Gore SD, Carducci MA.  Modifying histones to tame cancer: Clinical development of sodium phenylbutyrate and other histone deacetlase inhibitors.  Expert Opin Investig Drugs. 2000; 9: 2923-2934.

  13. Walczak J, Wood H, Wilding G, Carducci M. Prostate cancer prevention strategies using anti-proliferative or differentiating agents.  Urol. 2001; 57(4A):81-85.

  14. Carducci MA.  New chemotherapeutic approaches to hormone refractory prostate cancer. Cancer Control. 2001; 8: 62-65.

  15. Levy MH, Weinstein SM, Carducci MA.  Palliative Care.  Cancer Control. 2001; 8: 66-71.

  16. Kopetz S, Nelson JB, Carducci MA.  Endothelin-1 as a therapeutic target in prostate cancer.  Inv New Drug. 2002; 20:173-182.

  17. Walczak J, Carducci MA.  Pharmacologic therapies for prostate cancer.  Expert Opin Investig Drugs. 2002; 11: 1737-1748.

  18. Rosenbaum E, Carducci MA.  Pharmacotherapy of hormone refractory prostate cancer: New developments and challenges.  Expert Opin Pharmaocther. 2003; 4: 875-887.

  19. Lassiter LK, Carducci MA.  New approaches for the prevention of bone metastases in patients with prostate cancer: A review of preclinical and clinical studies.  Am J Cancer. 2003; 2: 181-199.

  20. Spira AI, Carducci MA.  Differentiation therapy.  Current Opin Pharmacol.  2003; 3: 338-343.

  21. Carducci MA.  Clinical trials of the endothelin-A receptor antagonist atrasentan in prostate cancer.   Cancer Conference Highlight.s 2003; 7: 6-8.

  22. Kahn M, Carducci MA, Partin AW.  The emerging role of docetaxel in the management of androgen independent prostate cancer.  J Urol. 2003; 170: 1709-1716.

  23. Lassiter LK, Carducci MA.  Endothelin receptor antagonists in the treatment of prostate cancer.  Semin Oncol. 2003; 30(5): 677-687.

  24. Dreicer R, Carducci M.  E1899 – An Eastern Cooperative Oncology Group study comparing ketoconazole and hydrocortisone with docetaxel and estramustine in asymptomatic, androgen independent prostate cancer patients with a rising PSA.   Reviews in Urology. 2003; 5 (S3): S52-S58.

  25. Walczak JR, Carducci MA.  Rising PSA in patients with asymptomatic hormone refractory prostate cancer.  Urology. 2003; 62 (Supp 6B): 141-146.

  26. Carducci MA, Tewari A, Bartsch G, Brawer MK, Crawford ED, D’Amico AV, Petrylak DP, Wilt TJ. 
    Prostate cancer update: Advanced disease.  Reviews in Urology. 2003; 5(S6): S47 –53.

  27. Petrylak DP, Abrahamson P-A, Bartsch G, Carducci MA. Small EJ, Wilding G.  Hormone-refractory prostate cancer: New Horizons.  Reviews in Urology. 2003; 5(S6): S54–58.

  28. Carducci MA.  Genitourinary Cancers –Highlights from the 40th Annual Meeting of the American Society of Clinical Oncology.  Clin Advanc Hematol Oncol. 2004; 2: 521-522.

  29. Jimeno A, Carducci MA.  Atrasentan: Targeting the endothelin axis in cancer.  Expert Opin Invest Drugs. 2004; 13: 1631-1640.

  30. Khan MA, Carducci MA, Partin AW.  Docetaxel in androgen-independent prostate cancer: an update.  BJU Int. 20004; 94: 1209-1210.

  31. Alumkal JJ, Carducci MA.  The early use of chemotherapy in conjunction with radical prostatectomy.  Clin Prostate Cancer. 2004; 3: 144-149.

  32. Walczak JR, Carducci MA.  The use of docetaxel in prostate cancer: A commentary on the Eastern Cooperative Oncology Group Study E1899.   Am J Urol Review. 2004; 2 (S9): 1-5.

  33. Shabbeer S, Carducci MA.  Targeting deacetylation for therapeutic benefit.  IDrugs.  2005; 8: 144-154.

  34. Browner I, Carducci MA.  Palliative chemotherapy: Historical perspective, applications, and controversies.  Semin Oncol.  2005; 32: 145-155.

  35. Armstrong AJ, Carducci MA. Novel therapeutic approaches to advanced prostate cancer.  Clin Advances Hematol Onco. 2005; 3: 271- 282.

  36. Armstrong AJ, Carducci MA.  Chemotherapy for advanced prostate cancer: results of new clinical trials and future studies.  Curr Oncol Rep. 2005; 7: 220-227.

  37. Armstrong A, Carducci MA.  Advanced prostate cancer: The future.  Canadian J Urol. 2005; 12 (Suppl 2): 42-47.

  38. Jimeno A, Carducci M.  Atrasentan: A novel and rationally designed therapeutic alternative for the management of cancer.  Expert Review of Anticancer Therapy. 2005; 5: 419-427.

  39. Armstrong AJ, Carducci MA. New drugs in prostate cancer.  Curr Opin Urol. 2006; 16: 138-145.

  40. Jimeno A, Carducci M.  Atrasentan: A rationally designed targeted therapy for cancer.  Drugs Today. 2006; 42: 299-312.

  41. Heath EI, Carducci MA. New targets in the management of prostate cancer.  Hematol Oncol Clin N Am.  2006; 20: 985-999.

  42. Carducci MA, Jimeno A.  Targeting bone metastasis in prostate cancer with endothelin receptor antagonists.  Clin Cancer Res. 2006; 12: 6296s-6300s.

  43. Messersmith WA, Hidalgo M, Carducci M, Eckhardt SG.  Novel targets in solid tumors: MEK Inhibitors. Clin Advances Hematol Onco. 2006; 4: 831-836.

  44. Kortenhorst MSQ, Carducci MA, Shabbeer S. Acetylation and histone deacetylase inhibitors in cancer.  Cellul Oncol. 2006; 28: 191-222.

  45. Walczak JR, Carducci MA.  Prostate cancer: A practical approach to current management of reccurrent disease.  Mayo Clinic Proc, 2007; 82:243-249.

  46. Morris MJ, Basch EM, Wilding G, Hussain M, Carducci MA, Higano C, Kantoff P, Oh WK, Small EJ, George D, Mathew P, Beer TM, Slovin SF, Ryan C, Logothetis C, Scher HI.  Department of Defense Prostate Cancer Clinical Trials Consortium: A new instrument for prostate cancer clinical research.  Clin Genitourinary Cancer, 2009; 7:51-57.  
U.S. News and World Report Rankings Badge

 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.| Disclaimer
Email: webmaster@urology.jhu.edu | 600 North Wolfe Street, Baltimore, Maryland 21287